Herpes Zoster em idosos: uma visão acerca da prevenção

Giulia Ellen Alves de Oliveira; Igor Marcelo Castro e Silva

doi:10.14295/idonline.v17i66.3732

Autores

Giulia Ellen Alves de Oliveira Hospital Universitário Presidente Dutra- HUUFMA
Igor Marcelo Castro e Silva Universidade Federal do MaranhãoUniversidade CEUMA https://orcid.org/0000-0002-1224-4577

DOI:

https://doi.org/10.14295/idonline.v17i66.3732

Palavras-chave:

Vacina, Idoso, Herpes Zoster

Resumo

INTRODUÇÃO: O vírus varicela-zoster é um herpesvírus que causa a varicela como infecção primária. Este permanece latente durante a vida e pode ser reativado na forma de herpes zóster, o que mais comumente ocorre em pessoas idosas. O objetivo deste artigo é revisar aspectos relacionados a prevenção do herpes zoster em idosos. MÉTODOS: O estudo foi realizado por levantamento bibliográfico utilizando as palavras-chave “ Herpes Zoster”, “Idosos”, “Vacina” nos bancos de dados MEDLINE, SciELO, BIREME, sendo selecionados artigos publicados na língua portuguesa e inglesa. A busca se deu no período de março a novembro de 2022. Para a profilaxia do herpes zoster atualmente estão disponíveis duas vacinas, a vacina viva atenuada e a vacina recombinante inativada. Maior eficácia, declínio mais lento da imunidade e a possibilidade de uso em imunocomprometidos justificam a superioridade da vacina inativada em relação a vacina atenuada. CONCLUSÃO: Considerando que o herpes zoster e suas complicações tem grande impacto na qualidade de vida dos idosos no que se refere a dor crônica e redução da funcionalidade, faz- se necessária a instalação de políticas públicas de saúde para garantir o acesso da pessoa idosa às vacinas disponíveis.

Downloads

Não há dados estatísticos.

Biografia do Autor

Giulia Ellen Alves de Oliveira, Hospital Universitário Presidente Dutra- HUUFMA

Médica residente do Programa de Residência Médica de Geriatria do Hospital Universitário Presidente Dutra- HUUFMA

Igor Marcelo Castro e Silva, Universidade Federal do MaranhãoUniversidade CEUMA

Graduado em Medicina pela Universidade CEUMA e Farmácia pela Univesidade Federal do Maranhão, especialização em Saúde da Família pela Universidade Castelo Branco-RJ, residência médica em Clínica Médica pela Universidade Federal do Ceará, residência médica em Oncologia Clínica pela Liga Bahiana Contra o Câncer, mestrado em Saúde e Ambiente pela Universidade Federal do Maranhão. Docente do Departamento de Patologia da Universidade Federal do Maranhão e do Curso de Medicina da Universidade CEUMA.

Referências

ATTAL, Nadine; MARTINEZ, Valéria; BOUHASSIRA, Didier. Potential for increased prevalence of neuropathic pain after the COVID-19 pandemic. Pain reports, v. 6, n. 1, 2021. DOI: https://doi.org/10.1097/PR9.0000000000000884

CAPUTO, Mahrrouz et al. Herpes zoster incidence in Germany-an indirect validation study for self-reported disease data from pretest studies of the population-based German National Cohort. BMC infectious diseases, v. 19, n. 1, p. 1-8, 2019. DOI: https://doi.org/10.1186/s12879-019-3691-2

COHEN, J. Varicella-zoster virus replication, pathogenesis, and management. Fields virology, v. 2, p. 2773-2818, 2006.

CUNNINGHAM, Anthony L. et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. New England Journal of Medicine, v. 375, n. 11, p. 1019-1032, 2016.

DOOLING, Kathleen L. et al. Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines. American Journal of Transplantation, v. 18, n. 3, p. 756-762, 2018. DOI: https://doi.org/10.1111/ajt.14683

DWORKIN, Robert H. et al. Recommendations for the management of herpes zoster. Clinical infectious diseases, v. 44, n. Supplement_1, p. S1-S26, 2007. DOI: https://doi.org/10.1086/510206

ESTATISTICA, Instituto Brasileiro De Geografia. Contingente de idosos residentes no Brasil aumenta 39,8% em 9 anos. Disponivel em: https:// agenciabrasil.ebc.com.br/ geral/noticia/2022-07/contingente-de-idosos-residentes-no-brasil-aumenta-398-em-9-anos. Acesso em: 23 de jan. 2023.

European EudraVigilance Database This Vaccination. Available online: http://www.adrreports.eu. Acesso em: 01 de fev. 2023

GILDEN, Donald H. et al. Neurologic complications of the reactivation of varicella–zoster virus. New England Journal of Medicine, v. 342, n. 9, p. 635-645, 2000. DOI: https://doi.org/10.1056/NEJM200003023420906

GODEAUX, Olivier et al. Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults≥ 50 years of age with a prior history of herpes zoster: a phase III, non-randomized, open-label clinical trial. Human vaccines & immunotherapeutics, v. 13, n. 5, p. 1051-1058, 2017. DOI: https://doi.org/10.1080/21645515.2016.1265715

GRINT, Daniel J. et al. Safety of inadvertent administration of live zoster vaccine to immunosuppressed individuals in a UK-based observational cohort analysis. BMJ open, v. 10, n. 1, p. e034886, 2020. DOI: https://doi.org/10.1136/bmjopen-2019-034886

HARBECKE, Ruth; COHEN, Jeffrey I.; OXMAN, Michael N. Herpes zoster vaccines. The Journal of Infectious Diseases, v. 224, n. Supplement_4, p. S429-S442, 2021. DOI: https://doi.org/10.1093/infdis/jiab387

HARPAZ, Rafael; ORTEGA-SANCHEZ, Ismael R.; SEWARD, Jane F. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report: Recommendations and Reports, v. 57, n. 5, p. 1-30, 2008.

HEYMANN, Warren R. The herpes zoster vaccine. Journal of the American Academy of Dermatology, v. 58, n. 5, p. 872-873, 2008. DOI: https://doi.org/10.1016/j.jaad.2007.09.013

HOPE-SIMPSON, R. Edgar. The nature of herpes zoster: a long-term study and a new hypothesis. 1965. DOI: https://doi.org/10.1177/003591576505800106

IMUNIZAÇÕES, Sociedade Brasileira. Vacinas Dsponiveis: Vacina Herpes Zoster Atenuada. Disponivel em: https://familia.sbim.org.br/vacinas/vacinas-disponiveis. Acesso em: 14 de fev 2023.

IWANAGA, Joe et al. A narrative review and clinical anatomy of herpes zoster infection following COVID‐19 vaccination. Clinical Anatomy, v. 35, n. 1, p. 45-51, 2022. DOI: https://doi.org/10.1002/ca.23790

JIH, Jaw-Shyang et al. Epidemiological features and costs of herpes zoster in Taiwan: a national study 2000 to 2006. Acta dermato-venereologica, v. 89, n. 6, 2009. DOI: https://doi.org/10.2340/00015555-0729

KAWAI, Kosuke; GEBREMESKEL, Berhanu G.; ACOSTA, Camilo J. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ open, v. 4, n. 6, p. e004833, 2014. DOI: https://doi.org/10.1136/bmjopen-2014-004833

KOSHY, Elsam et al. Epidemiology, treatment and prevention of herpes zoster: A comprehensive review. Indian Journal of Dermatology, Venereology and Leprology, v. 84, p. 251, 2018. DOI: https://doi.org/10.4103/ijdvl.IJDVL_1021_16

KUDESIA, G. et al. Changes in age related seroprevalence of antibody to varicella zoster virus: impact on vaccine strategy. Journal of clinical pathology, v. 55, n. 2, p. 154-155, 2002. DOI: https://doi.org/10.1136/jcp.55.2.154

LAL, Himal et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. New England Journal of Medicine, v. 372, n. 22, p. 2087-2096, 2015. DOI: https://doi.org/10.1056/NEJMoa1501184

LEVIN, Myron J. et al. Studies with herpes zoster vaccines in immune compromised patients. Expert review of vaccines, v. 16, n. 12, p. 1217-1230, 2017. DOI: https://doi.org/10.1080/14760584.2017.1395703

LIAO, Chun-Hui et al. High prevalence of herpes zoster in patients with depression. The Journal of Clinical Psychiatry, v. 76, n. 9, p. 8230, 2015. DOI: https://doi.org/10.4088/JCP.14m09311

MAREQUE, M. et al. Systematic review of the evidence on the epidemiology of herpes zoster: incidence in the general population and specific subpopulations in Spain. Public Health, v. 167, p. 136-146, 2019. DOI: https://doi.org/10.1016/j.puhe.2018.10.015

MOFFAT, Jennifer et al. VZV: pathogenesis and the disease consequences of primary infection. Human herpesviruses: biology, therapy, and immunoprophylaxis, 2007. DOI: https://doi.org/10.1017/CBO9780511545313.038

MOHTA, Alpana et al. Recurrent herpes zoster after COVID‐19 vaccination in patients with chronic urticaria being treated with cyclosporine—A report of 3 cases. Journal of Cosmetic Dermatology, v. 20, n. 11, p. 3384, 2021. DOI: https://doi.org/10.1111/jocd.14437

MORRISON, Vicki A. et al. Long-term persistence of zoster vaccine efficacy. Clinical infectious diseases, v. 60, n. 6, p. 900-909, 2015.

MUNOZ-QUILES, Cintia et al. Risk and impact of herpes zoster on patients with diabetes: a population-based study, 2009–2014. Human vaccines & immunotherapeutics, v. 13, n. 11, p. 2606-2611, 2017. DOI: https://doi.org/10.1080/21645515.2017.1368600

NETO, Lauro; KFOURI, Renato. Nota Técnica – 08/06/2022, Vacina herpes-zóster inativada recombinante (Shingrix®). Sociedade Brasileira de Imunizações. 2022

NIEDERER, Rachel Louise et al. Herpes zoster ophthalmicus clinical presentation and risk factors for loss of vision. American Journal of Ophthalmology, v. 226, p. 83-89, 2021. DOI: https://doi.org/10.1016/j.ajo.2021.02.002

NOFAL, Ahmad et al. Herpes zoster ophthalmicus in COVID‐19 patients. International Journal of Dermatology, v. 59, n. 12, p. 1545, 2020. DOI: https://doi.org/10.1111/ijd.15240

OXMAN, Michael N. et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine, v. 352, n. 22, p. 2271-2284, 2005.

PONA, Adrian et al. Herpes zoster as a potential complication of coronavirus disease 2019. Dermatologic therapy, v. 33, n. 6, 2020. DOI: https://doi.org/10.1111/dth.13930

RIMLAND, David; MOANNA, Abeer. Increasing incidence of herpes zoster among veterans. Clinical infectious diseases, v. 50, n. 7, p. 1000-1005, 2010. DOI: https://doi.org/10.1086/651078

SCHMADER, K. E. et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical infectious diseases, v. 55, n. 10, p. 1320-1328, 2012. DOI: https://doi.org/10.1093/cid/cis638

SCHMADER, Kenneth E. et al. Effect of a Zoster Vaccine on Herpes Zoster–Related Interference with Functional Status and Health‐Related Quality‐of‐Life Measures in Older Adults. Journal of the American Geriatrics Society, v. 58, n. 9, p. 1634-1641, 2010. DOI: https://doi.org/10.1111/j.1532-5415.2010.03021.x

SCHMADER, Kenneth E. et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50–59 years. Clinical infectious diseases, v. 54, n. 7, p. 922-928, 2012. DOI: https://doi.org/10.1093/cid/cir970

SYED, Yahiya Y. Recombinant zoster vaccine (Shingrix®): a review in herpes zoster. Drugs & aging, v. 35, p. 1031-1040, 2018. DOI: https://doi.org/10.1007/s40266-018-0603-x

UNIDAS, Nações. World Population Prospects - 2017 Revision: Global population. Disponivel em: https://www.un.org/pt/desa/world-population-prospects-2017-revision-global-population. Acesso em: 15 de fev. 2023.

United States Vaccine Adverse Event Report System (VAERS). Disponivel em: https://wonder.cdc.gov/vaers.html. Acesso em: 13 de fev. 2023.

VAN OORSCHOT, Désirée et al. A systematic literature review of herpes zoster incidence worldwide. Human Vaccines & Immunotherapeutics, v. 17, n. 6, p. 1714-1732, 2021. DOI: https://doi.org/10.1080/21645515.2020.1847582

VARGHESE, Lijoy et al. The temporal impact of aging on the burden of herpes zoster. BMC geriatrics, v. 17, n. 1, p. 1-7, 2017. DOI: https://doi.org/10.1186/s12877-017-0420-9

YAWN, Barbara P. et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. In: Mayo Clinic Proceedings. Elsevier, 2007. p. 1341-1349. DOI: https://doi.org/10.4065/82.11.1341

YU, Ana Lúcia Frugis et al. Three year seroepidemiological study of varicella-zoster virus in São Paulo, Brazil. Revista do Instituto de Medicina Tropical de São Paulo, v. 42, p. 125-128, 2000. DOI: https://doi.org/10.1590/S0036-46652000000300002